vs
Apellis Pharmaceuticals, Inc.（APLS）与Offerpad Solutions Inc.（OPAD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Offerpad Solutions Inc.的1.8倍（$199.9M vs $114.1M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -34.5%），Offerpad Solutions Inc.自由现金流更多（$65.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -36.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Offerpad Solutions Inc是美国知名房地产科技企业，专注于简化住宅房产交易流程，采用iBuyer模式直接向卖家收购房屋，完成翻新后挂牌出售，同时提供按揭、产权服务、灵活搬迁方案等配套服务，业务覆盖美国数十个州。
APLS vs OPAD — 直观对比
营收规模更大
APLS
是对方的1.8倍
$114.1M
营收增速更快
APLS
高出28.6%
-34.5%
自由现金流更多
OPAD
多$80.0M
$-14.3M
两年增速更快
APLS
近两年复合增速
-36.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $114.1M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 7.0% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -34.5% |
| 净利润同比 | -62.2% | 49.1% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSOPAD
| Q4 25 | $199.9M | $114.1M | ||
| Q3 25 | $458.6M | $132.7M | ||
| Q2 25 | $178.5M | $160.3M | ||
| Q1 25 | $166.8M | $160.7M | ||
| Q4 24 | $212.5M | $174.3M | ||
| Q3 24 | $196.8M | $208.1M | ||
| Q2 24 | $199.7M | $251.1M | ||
| Q1 24 | $172.3M | $285.4M |
净利润APLSOPAD
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-11.6M | ||
| Q2 25 | $-42.2M | $-10.9M | ||
| Q1 25 | $-92.2M | $-15.1M | ||
| Q4 24 | $-36.4M | $-17.3M | ||
| Q3 24 | $-57.4M | $-13.5M | ||
| Q2 24 | $-37.7M | $-13.8M | ||
| Q1 24 | $-66.4M | $-17.5M |
毛利率APLSOPAD
| Q4 25 | — | 7.0% | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | — | 8.9% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | — | 7.9% |
营业利润率APLSOPAD
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | -5.1% | ||
| Q2 25 | -18.6% | -4.9% | ||
| Q1 25 | -50.0% | -7.2% | ||
| Q4 24 | -12.3% | -7.8% | ||
| Q3 24 | -24.0% | -4.3% | ||
| Q2 24 | -14.7% | -3.9% | ||
| Q1 24 | -36.0% | -4.8% |
净利率APLSOPAD
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -8.7% | ||
| Q2 25 | -23.6% | -6.8% | ||
| Q1 25 | -55.3% | -9.4% | ||
| Q4 24 | -17.1% | -9.9% | ||
| Q3 24 | -29.2% | -6.5% | ||
| Q2 24 | -18.9% | -5.5% | ||
| Q1 24 | -38.5% | -6.1% |
每股收益（稀释后）APLSOPAD
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $-0.37 | ||
| Q2 25 | $-0.33 | $-0.39 | ||
| Q1 25 | $-0.74 | $-0.55 | ||
| Q4 24 | $-0.30 | $-0.64 | ||
| Q3 24 | $-0.46 | $-0.49 | ||
| Q2 24 | $-0.30 | $-0.50 | ||
| Q1 24 | $-0.54 | $-0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $26.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $38.2M |
| 总资产 | $1.1B | $154.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSOPAD
| Q4 25 | $466.2M | $26.5M | ||
| Q3 25 | $479.2M | $31.0M | ||
| Q2 25 | $370.0M | $22.6M | ||
| Q1 25 | $358.4M | $30.8M | ||
| Q4 24 | $411.3M | $43.0M | ||
| Q3 24 | $396.9M | $48.5M | ||
| Q2 24 | $360.1M | $56.9M | ||
| Q1 24 | $325.9M | $68.5M |
总债务APLSOPAD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSOPAD
| Q4 25 | $370.1M | $38.2M | ||
| Q3 25 | $401.2M | $39.9M | ||
| Q2 25 | $156.3M | $24.5M | ||
| Q1 25 | $164.2M | $34.2M | ||
| Q4 24 | $228.5M | $47.7M | ||
| Q3 24 | $237.1M | $64.7M | ||
| Q2 24 | $264.3M | $77.6M | ||
| Q1 24 | $266.7M | $88.1M |
总资产APLSOPAD
| Q4 25 | $1.1B | $154.8M | ||
| Q3 25 | $1.1B | $223.5M | ||
| Q2 25 | $821.4M | $268.0M | ||
| Q1 25 | $807.3M | $274.5M | ||
| Q4 24 | $885.1M | $313.1M | ||
| Q3 24 | $901.9M | $338.5M | ||
| Q2 24 | $904.5M | $406.6M | ||
| Q1 24 | $831.9M | $369.7M |
负债/权益比APLSOPAD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $66.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $65.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 57.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSOPAD
| Q4 25 | $-14.2M | $66.8M | ||
| Q3 25 | $108.5M | $40.0M | ||
| Q2 25 | $4.4M | $-13.5M | ||
| Q1 25 | $-53.4M | $-10.2M | ||
| Q4 24 | $19.4M | $20.8M | ||
| Q3 24 | $34.1M | $39.6M | ||
| Q2 24 | $-8.3M | $-54.4M | ||
| Q1 24 | $-133.0M | $2.4M |
自由现金流APLSOPAD
| Q4 25 | $-14.3M | $65.7M | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $-13.6M | ||
| Q1 25 | $-53.4M | $-11.2M | ||
| Q4 24 | $19.3M | $15.4M | ||
| Q3 24 | — | $38.7M | ||
| Q2 24 | $-8.4M | $-54.4M | ||
| Q1 24 | $-133.3M | $2.0M |
自由现金流率APLSOPAD
| Q4 25 | -7.1% | 57.6% | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | -8.5% | ||
| Q1 25 | -32.0% | -7.0% | ||
| Q4 24 | 9.1% | 8.9% | ||
| Q3 24 | — | 18.6% | ||
| Q2 24 | -4.2% | -21.7% | ||
| Q1 24 | -77.3% | 0.7% |
资本支出强度APLSOPAD
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 3.1% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSOPAD
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
OPAD
暂无分部数据
